newsfilter
← Latest News
Business Wire·

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

Signed term sheet with strategic partner to enhance distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol to IRBs for